INS.L Regulatory News (INS)

10 August 2011

Instem Life Science Systems plc

("Instem", the "Company" or the "Group")

Notification of Death of Director

It is with deep regret that the Board of Instem plc (AIM: INS) announces that Jim McLauchlan, Chief Financial Officer, passed away suddenly on 8 August. Jim had been with Instem since 2003, during which time he provided an invaluable contribution to the Company.

Phil Reason, Chief Executive, commented, "On behalf of everyone at Instem, I would like to express our heartfelt condolences to Jim's family. Jim worked closely with many people across the business as we built the strong foundation that led to our IPO last October. I could not have wished for a more committed colleague or enjoyable companion when spending intensive periods together in the City. I am glad Jim had the opportunity to enjoy being part of our first post-IPO acquisition and that he could be rightly proud of the strong team and legacy that he has left with us. Jim will be deeply missed by us all."

David Sherwin, current Non-executive Director of the Company has been appointed as interim Chief Financial Officer while the Board considers permanent succession arrangements. David, a founder of Instem, is a qualified accountant and experienced finance director, having been Chief Financial Officer of Instem's former parent between 1979 and 1998, including 14 years when it was public on the USM and main market.

For further information, please contact:

About Instem Life Science Systems plc

Instem (AIM:INS.L) is a world-leading information solutions provider to the life sciences - accelerating drug and chemical development by increasing client productivity and enhancing the processes that lead to safer, more effective products. In addition to highly focused departmental and scientific solutions, Instem provides a range of business intelligence, planning, workflow management, document management and report compilation applications.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.

To learn more about Instem solutions and its mission, please visit www.instem.com.